Boston completes Prolieve acquisition:
This article was originally published in Clinica
Executive Summary
Boston Scientific has closed its acquisition of Celsion's Prolieve technology for treating symptomatic benign prostatic hyperplasia. The two companies had agreed to the $60m transaction in April 2007 (see Clinica No 1253, p 12). Celsion will use the proceeds to fund its ThermoDox liver cancer drug programme.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.